(RxWiki News) As a new year begins, we celebrate the beginning of something new and exciting. This year, that includes several new medication approvals from the US Food and Drug Administration (FDA).
The FDA recently approved the following medications:
1) Lynparza (olaparib) has been approved to treat adults with advanced breast cancer with a certain inherited genetic mutation. In this case, Lynparza is approved to treat a type of human epidermal growth factor receptor 2-negative breast cancer that has an abnormal inherited BRCA gene. This medication was approved in 2014 to treat a certain type of ovarian cancer.
2) Lumify (brimonidine tartrate) has been approved to treat eye redness. Lumify offers low-dose brimonidine tartrate in the form of eye drops and is actually available over the counter. In 1996, brimonidine was approved in a higher dose to lower intraocular pressure in patients with glaucoma.
3) Steglatro (ertugliflozin) tablets, Steglujan (ertugliflozin and sitagliptin) tablets and Segluromet (ertugliflozin and metformin HCL) were all approved to treat adults with type 2 diabetes mellitus.
4) Giapreza (angiotensin II) injection was approved to treat very low blood pressure. This medication increases blood pressure in adults with septic or other distributive shock, according to the FDA.
5) Impoyz (clobetasol propionate) has been approved to treat moderate to severe plaque psoriasis.
Speak with your health care provider if you have any questions about new treatments for your condition.